Zivo Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $25.96M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Zivo Bioscience has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Zivo Bioscience filed with the SEC
ZIVO BIOSCIENCE, INC. ANNOUNCES INTENTION TO FILE FORM 15 TO VOLUNTARILY DEREGISTER AND SUSPEND ITS SEC REPORTING OBLIGATIONS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
From the Office of the CEO — John B. Payne
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
Regulation FD disclosure · EX-99.1 to Form 8-K
ZIVO Bioscience Receives $1 Million Bridge Financing
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
White Paper Submission to USDA
Regulation FD disclosure · EX-99.1 to Form 8-K
CORPORATE UPDATE, DATED MAY 20, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 10, 2022
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K